At the AAIC 2026 Conference in London, NeuroTherapia will unveil data from its Phase 2a clinical trial of NTRX-07 for Alzheimer's disease, highlighting significant safety and biomarker results.

Encouraging Data Demonstrating Target Engagement will be Presented in a Poster on Monday July 13ᵗʰ CLEVELAND, July 13, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, will be presenting data from its...

NeuroTherapia has concluded its Phase IIa clinical trial of NTRX-07, an orally available molecule, for Alzheimer's disease treatment.

NeuroTherapia has successfully finished its Phase 2a trial for a new Alzheimer's drug, showcasing safety and encouraging early results that pave the way for future studies.

NeuroTherapia has received EMA approval for its Phase 2 trial of NTRX-07 for Alzheimer's, focusing on safety, pharmacokinetics, and efficacy.